These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37802600)

  • 1. Longitudinal associations between body mass index and changes in disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab.
    Burkard T; Vallejo-Yagüe E; Lauper K; Finckh A; Hügle T; Burden AM
    RMD Open; 2023 Oct; 9(4):. PubMed ID: 37802600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Body mass index and clinical response to infliximab in rheumatoid arthritis.
    Klaasen R; Wijbrandts CA; Gerlag DM; Tak PP
    Arthritis Rheum; 2011 Feb; 63(2):359-64. PubMed ID: 21279992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Body Mass Index Categories with Disease Activity and Radiographic Joint Damage in Rheumatoid Arthritis: A Systematic Review and Metaanalysis.
    Vidal C; Barnetche T; Morel J; Combe B; Daïen C
    J Rheumatol; 2015 Dec; 42(12):2261-9. PubMed ID: 26523023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lower concentration of vitamin D is associated with lower DAS28 and VAS-pain scores in patients with inflammatory rheumatic diseases treated with infliximab: a pilot study.
    Miler M; Nikolac Gabaj N; Grazio S; Vahtarić A; Vrtarić A; Grubišić F; Skala Kavanagh H; Doko Vajdić I; Vrkić N
    Rheumatol Int; 2020 Sep; 40(9):1455-1461. PubMed ID: 32462255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calprotectin (S100A8/A9) and S100A12 are associated with measures of disease activity in a longitudinal study of patients with rheumatoid arthritis treated with infliximab.
    Nordal HH; Brun JG; Hordvik M; Eidsheim M; Jonsson R; Halse AK
    Scand J Rheumatol; 2016 Jul; 45(4):274-81. PubMed ID: 26767827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice.
    Hirata S; Li W; Kubo S; Fukuyo S; Mizuno Y; Hanami K; Sawamukai N; Yamaoka K; Saito K; Defranoux NA; Tanaka Y
    Mod Rheumatol; 2016 Nov; 26(6):850-856. PubMed ID: 26873570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Body mass index and treatment survival in patients with RA starting treatment with TNFα-inhibitors: long-term follow-up in the real-life METEOR registry.
    Bergstra SA; Allaart CF; Vega-Morales D; De Buck M; Murphy E; Salomon Escoto K; Huizinga TWJ
    RMD Open; 2020 Jun; 6(2):. PubMed ID: 32506054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: A retrospective observational study.
    Hirata S; Li W; Defranoux N; Cavet G; Bolce R; Yamaoka K; Saito K; Tanaka Y
    Mod Rheumatol; 2015 May; 25(3):344-9. PubMed ID: 25295918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab equivalently suppresses oxidative stress compared to tocilizumab among well-controlled patients with rheumatoid arthritis.
    Kizaki K; Yamashita F; Hayashi T; Funakoshi N
    Int J Rheum Dis; 2018 Oct; 21(10):1815-1821. PubMed ID: 27778459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
    Smolen JS; Han C; Bala M; Maini RN; Kalden JR; van der Heijde D; Breedveld FC; Furst DE; Lipsky PE;
    Arthritis Rheum; 2005 Apr; 52(4):1020-30. PubMed ID: 15818697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is radiographic progression of late-onset rheumatoid arthritis different from young-onset rheumatoid arthritis? Results from the Swiss prospective observational cohort.
    Mueller RB; Kaegi T; Finckh A; Haile SR; Schulze-Koops H; von Kempis J;
    Rheumatology (Oxford); 2014 Apr; 53(4):671-7. PubMed ID: 24352338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiographic progression can still occur in individual patients with low or moderate disease activity in the current treat-to-target paradigm: real-world data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
    Ten Klooster PM; Versteeg LGA; Oude Voshaar MAH; de la Torre I; De Leonardis F; Fakhouri W; Zaremba-Pechmann L; van de Laar M
    Arthritis Res Ther; 2019 Nov; 21(1):237. PubMed ID: 31718678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association between increased body mass index and response to conventional synthetic disease-modifying anti-rheumatic drug treatment in rheumatoid arthritis: results from the METEOR database.
    Dey M; Zhao SS; Moots RJ; Bergstra SA; Landewe RB; Goodson NJ
    Rheumatology (Oxford); 2022 Feb; 61(2):713-722. PubMed ID: 33930113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab.
    Sung YK; Cho SK; Kim D; Won S; Choi CB; Bang SY; Hong SJ; Kim HA; Koh EM; Lee HS; Suh CH; Yoo DH; Bae SC
    Rheumatol Int; 2017 Jun; 37(6):1007-1014. PubMed ID: 28214924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
    Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML
    J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obesity reduces the drug survival of second line biological drugs following a first TNF-α inhibitor in rheumatoid arthritis patients.
    Iannone F; Fanizzi R; Notarnicola A; Scioscia C; Anelli MG; Lapadula G
    Joint Bone Spine; 2015 May; 82(3):187-91. PubMed ID: 25619156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: systematic reviews.
    Archer R; Hock E; Hamilton J; Stevens J; Essat M; Poku E; Clowes M; Pandor A; Stevenson M
    Health Technol Assess; 2018 Nov; 22(66):1-294. PubMed ID: 30501821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Body Mass Index Impact on Disease Activity, Clinical and Sonographic Remission Rates in Patients with Rheumatoid Arthritis.
    Sapundzhieva T; Karalilova R; Batalov A
    Curr Rheumatol Rev; 2019; 15(3):215-223. PubMed ID: 30499417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies.
    Roodenrijs NMT; de Hair MJH; Wheater G; Elshahaly M; Tekstra J; Teng YKO; Lafeber FPJG; Hwang CC; Liu X; Sasso EH; van Laar JM
    Arthritis Res Ther; 2018 Nov; 20(1):256. PubMed ID: 30458871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Changes in the Adipose Tissue Induced by Rheumatoid Arthritis: Effects of Disease-Modifying Anti-Rheumatic Drugs.
    Arias de la Rosa I; Escudero-Contreras A; Ruiz-Ponce M; Román-Rodríguez C; Pérez-Sánchez C; Ábalos-Aguilera MDC; Ortega-Castro R; Alcaide J; Murri M; Font P; Calvo-Gutiérrez J; Luque-Tevar M; Patiño-Trives AM; Guzmán-Ruiz R; Malagón MDM; Tinahones FJ; Collantes-Estévez E; López-Pedrera C; Barbarroja N
    Front Immunol; 2021; 12():744022. PubMed ID: 34721412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.